Baxter signs blood pact with Laboratoire Francais du Fractionnement et des Biotechnologies (LFB):
This article was originally published in Clinica
Executive Summary
French blood company Laboratoire Francais du Fractionnement et des Biotechnologies will distribute Baxter's HemAssist, an oxygen-carrying haemoglobin, in France. LFB has the monopoly on the production of blood derivatives from plasma collected in France. The two companies will invest Fr 200 million ($40 million) in a new production unit at LFB's Lille headquarters, for which Baxter will provide the production equipment. HemAssist is undergoing clinical trials on over 600 patients in the US and Europe and is expected to be launched by the beginning of 1998.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.